A newly developed uroplakin ii antibody with increased sensitivity in urothelial carcinoma of the bladder

Archives of Pathology and Laboratory Medicine

Volumn 138, Issue 7, 2014, Pages 943-949

  Hoang, Laura L ^a   Tacha, David E ^a   Qi, Weimin ^a   Yu, Charlie ^a   Bremer, Ryan E ^a   Chu, Joseph ^a   Haas, Thomas S ^b   Cheng, Liang ^c  

^a Biocare Medical   (United States)

^b MERCY HEALTH SYSTEM   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER; UPK2 PROTEIN, HUMAN; UPK3A PROTEIN, HUMAN; UROPLAKIN 2; UROPLAKIN 3;

ANIMAL; ANTIBODY SPECIFICITY; ARTICLE; BLADDER TUMOR; COMPARATIVE STUDY; EVALUATION STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MOUSE; PREGNANCY; TISSUE DISTRIBUTION; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; PREGNANCY; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROPLAKIN II; UROPLAKIN III; UROTHELIUM;

EID: 84904011306     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2013-0221-OA     Document Type: Article

References (18)

1. American Cancer Society, Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society; 2012.
2. Frantzi M, Makridakis M, Vlahou A. Biomarkers for bladder cancer aggressiveness. Curr Opin Urol. 2012;22(5):390-396.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
4. Wu XR, Kong XP, Pellicer A, Kreibich G, Sun TT. Uroplakins in urothelial biology, function, and disease. Kidney Int. 2009;75(11):1153-1165.
5. Wu X, Kakehi Y, Zeng Y, Taoka R, Tsunemori H, Inui M. Uroplakin II as a promising marker for molecular diagnosis of nodal metastases from bladder cancer: Comparison with cytokeratin. J Urol. 2005;174(6):2138-2142.
6. Olsburgh J, Harnden P, Weeks R, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2003; 199(1):41-49.
7. Lu JJ, Kakehi Y, Takahashi T, et al. Detection of circulating cancer cells by reverse transcription-polymerase chain reaction for uroplakin II in peripheral blood of patients with urothelial cancer. Clin Cancer Res. 2000;6(8):3166-3171.
8. Li SM, Zhang ZT, Chan S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999; 162(3, pt 1):931-935.
9. Yuasa T, Yoshiki T, Isono T, Tanaka T, Okada Y. Molecular cloning and expression of uroplakins in transitional cell carcinoma. Adv Exp Med Biol. 2003; 539(pt A):33-46.
10. Okegawa T, Kinjo M, Nutahara K, Higashihara E. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol. 2004;171(4):1461-1466.
11. Huang HY, Shariat SF, Sun TT, et al. Persistent uroplakin expression in advanced urothelial carcinomas: Implications in urothelial tumor progression and clinical outcome. Hum Pathol. 2007;38(11):1703-1713.
12. Kong XT, Deng FM, Hu P, et al. Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases. J Cell Biol. 2004;167(6): 1195-1204.
13. Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995; 147(5): 1383-1397.
14. Lewis SA. Everything you wanted to know about the bladder epithelium but were afraid to ask. Am J Physiol Renal Physiol. 2000;278(6):F867-F874.
15. Kaufmann O, Volmerig J, Dietel M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am J Clin Pathol. 2000;113 (5):683-687.
16. Matsumoto K, Satoh T, Irie A, et al. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. Urology. 2008;72(2):444-449.
17. Ohtsuka Y, Kawakami S, Fujii Y, et al. Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006;97(6):1322-1326.
18. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006;37(6):726-734.